Tuberculosis-HIV co-infection: Progress and challenges after two decades of global antiretroviral treatment roll-out

Letang, EmilioEllis, JayneNaidoo, KogieleumCasas, Esther C.Sánchez, PaquitaHassan-Moosa, RaziaCresswell, FionaMiró Meda, José M. (José María), 1956-García-Basteiro, Alberto L.2020-07-072021-01-102020-01-100300-2896https://hdl.handle.net/2445/168021Despite wide antiretroviral scale-up during the past two decades resulting in declining new infections and mortality globally, HIV-associated tuberculosis remains as a major public health concern. Tuberculosis is the leading HIV-associated opportunistic infection and the main cause of death globally and, particularly, in resource-limited settings. Several challenges exist regarding diagnosis, global implementation of latent tuberculosis treatment, management of active tuberculosis, delivery of optimal patient-centered TB and HIV prevention and care in high burden countries. In this article we review the advances on pathogenesis, diagnosis, and treatment after nearly two decades of global roll-out of antiretroviral therapy and discuss the current challenges for the global control of tuberculosis-HIV co-infection.9 p.application/pdfengcc-by-nc-nd (c) Elsevier, 2020http://creativecommons.org/licenses/by-nc-nd/3.0/esTuberculosiVIH (Virus)AntiretroviralsTuberculosisHIV (Viruses)Antiretroviral agentsTuberculosis-HIV co-infection: Progress and challenges after two decades of global antiretroviral treatment roll-outinfo:eu-repo/semantics/article6958902020-07-07info:eu-repo/semantics/openAccess31932150